Core Insights - GenScript Biotech Corporation reported strong financial results for FY2025, with revenue reaching approximately US$959.5 million, a 61.4% increase year-on-year, and adjusted net profit rising to US$230.3 million, reflecting a 285.0% growth [2][4][6]. Group Performance - The company achieved a gross profit of approximately US$553.2 million, up 103.3% from US$272.1 million in 2024, driven by revenue expansion, particularly in biologics development services [5]. - Selling and distribution expenses increased by 12.9% to approximately US$99.5 million, attributed to the expansion of commercial teams and investments in regional operations [7]. - Administrative expenses rose by 12.4% to approximately US$128.6 million, mainly due to capacity expansion and initial expenses for a new site [8]. - R&D expenses increased by 32.4% to approximately US$71.2 million, driven by recruitment of skilled professionals and expansion of research initiatives [9]. Strategic Drivers of FY2025 Performance - Integrated platform synergies contributed approximately 65% of the revenue growth for the GenScript Life Science Group (LSG) [11]. - The company strengthened its global reach, with Europe and Asia-Pacific showing significant revenue growth of 29% and 33% year-on-year, respectively [12]. - GenScript advanced proprietary technologies and product platforms, enhancing differentiation and customer adoption in high-growth applications [13]. - Automation and digitalization efforts improved operational efficiency, with 60% of global production capacity expected to be powered by AI-driven automation by the end of 2026 [14]. Business Segment Highlights - GenScript Life Science Group generated US$522.1 million in revenue, up 14.8% year-on-year, benefiting from strong demand and adoption of its integrated gene-to-protein platform [15]. - ProBio experienced exceptional growth, with revenue reaching US$388.7 million, a 309.1% increase year-on-year, and secured multiple drug development projects [16]. - Bestzyme generated US$58.0 million in revenue, up 7.9% year-on-year, driven by advancements in industrial biotechnology and AI-enabled R&D capabilities [17]. Outlook - For 2026, GenScript anticipates continued growth driven by rising demand for integrated biotechnology platforms and advanced therapeutics development, with projected revenue growth rates of 10%-15% for Bestzyme, 20%-25% for ProBio, and 15%-18% for GenScript LSG [23].